Mike Collins

7PUBLICATIONS
68CO-AUTHORS
Medical molecular engineering of nucleic acids and proteinsMolecular targetsGene and molecular therapyAccelerators
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Feb 24, 2026
Overcoming menin inhibitor resistance in AML cells with combinations including BET proteins and a dual BRG1/BRM inhibitor.

Warren Fiskus, Christopher P Mill, Ghayas C Issa

|Dec 12, 2025
Prognostic Implications of SMARCA4, ARID1A, and Other BAF Mutations in Non-Small Cell Lung Cancer.

Alexis Khalil, Michael P Collins, Alfonso Quintás-Cardama

|Apr 16, 2025
A Phase I Study of FHD-286, a Dual BRG1/BRM (SMARCA4/SMARCA2) Inhibitor, in Patients with Advanced Myeloid Malignancies.

Courtney D DiNardo, Amir T Fathi, Ashwin Kishtagari

|Dec 11, 2024
A Phase I Study of FHD-609, a Heterobifunctional Degrader of Bromodomain-Containing Protein 9, in Patients with Advanced Synovial Sarcoma or SMARCB1-Deficient Tumors.

J Andrew Livingston, Jean-Yves Blay, Jonathan Trent

|Mar 04, 2024
BRG1/BRM inhibitor targets AML stem cells and exerts superior preclinical efficacy combined with BET or menin inhibitor.

Warren Fiskus, Jessica Piel, Mike Collins

|Sep 18, 2020
STAT3 Antisense Oligonucleotide Remodels the Suppressive Tumor Microenvironment to Enhance Immune Activation in Combination with Anti-PD-L1.

Theresa A Proia, Maneesh Singh, Richard Woessner

Pageof 2

Frequent Collaborators

3 joint publications

Courtney D DiNardo

3 joint publications

Alexis Khalil

3 joint publications

Sanam Loghavi

3 joint publications

Alfonso Quintás-Cardama